IP Library Granted Patent US 8,486,980
Granted Patent B2
US 8,486,980 · App. 13/057,599 · Granted Jul 16, 2013

Tricyclic compound

Inventors: Arata Yanagisawa (Shizuoka, JP); Keiji Uehara (Shizuoka, JP); Masahiro Matsubara (Shizuoka, JP); Kimihisa Ueno (Shizuoka, JP); Michihiko Suzuki (Shizuoka, JP); Takeshi Kuboyama (Shizuoka, JP); Keisuke Yamamoto (Shizuoka, JP); Tomohiro Tamura (Shizuoka, JP)
Assignee: Kyowa Hakko Kirin Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,486,980
App. No.
13/057,599
Granted
Jul 16, 2013
Kind
B2
Abstract

Provided is a tricyclic compound having a PPAR γ agonist activity, which is represented by the general formula (I) wherein Z represents a single bond or the like, Y represents a hydrogen atom, lower alkyl optionally having substituent(s) or the like, X represents a hydrogen atom or the like, A represents aryl or the like, B and C are the same or different and each represents an aromatic carbocycle or the like, R 4 -R 9 are the same or different and each represents hydrogen or the like, V represents a single bond or the like, R 10 and R 11 are the same or different and each represents hydrogen or the like, or a pharmaceutically acceptable salt thereof or the like:

Claims (23)

1. A tricyclic compound represented by formula

wherein

Y is a hydrogen atom, lower alkyl optionally having substituent(s), or cycloalkyl optionally having substituent(s),

Z is —CH 2 O— or —OCH 2 —,

R 8 is a hydrogen atom or halogen, and

A is an aromatic heterocyclic group optionally having substituent(s),

or a pharmaceutically acceptable salt thereof.

2. The tricyclic compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein A is group (a38) or (a39)

wherein

R 1A is lower alkyl optionally having substituent(s), aryl optionally having substituent(s), or cycloalkyl optionally having substituent(s), and

R L and R M are the same or different and each is a hydrogen atom, halogen, carbamoyl, lower alkylcarbamoyl optionally having substituent(s), lower alkyl optionally having substituent(s), or lower alkylsulfonylamino optionally having substituent(s).

3. The tricyclic compound or the pharmaceutically acceptable salt thereof according to claim 2 , wherein A is group (a38).

4. The tricyclic compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein Y is lower alkyl.

5. The tricyclic compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein Y is methyl.

6. The tricyclic compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein Z is —CH 2 O—.

7. The tricyclic compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 8 is a hydrogen atom.

8. A pharmaceutical composition comprising the tricyclic compound or the pharmaceutically acceptable salt thereof according to claim 1 , as an active ingredient.

9. A pharmaceutical composition comprising the tricyclic compound or the pharmaceutically acceptable salt thereof according to claim 2 , as an active ingredient.

10. A pharmaceutical composition comprising the tricyclic compound or the pharmaceutically acceptable salt thereof according to claim 3 , as an active ingredient.

11. A pharmaceutical composition comprising the tricyclic compound or the pharmaceutically acceptable salt thereof according to claim 4 , as an active ingredient.

12. A pharmaceutical composition comprising the tricyclic compound or the pharmaceutically acceptable salt thereof according to claim 5 , as an active ingredient.

13. A pharmaceutical composition comprising the tricyclic compound or the pharmaceutically acceptable salt thereof according to claim 6 , as an active ingredient.

14. A pharmaceutical composition comprising the tricyclic compound or the pharmaceutically acceptable salt thereof according to claim 7 , as an active ingredient.

Assignments (4)
ADDRESS CHANGE Recorded Dec 27, 2019
From: KYOWA KIRIN CO., LTD.
To: KYOWA KIRIN CO., LTD.
Reel/Frame 051429/0173 →
CHANGE OF NAME Recorded Dec 27, 2019
From: KYOWA HAKKO KIRIN CO., LTD.
To: KYOWA KIRIN CO., LTD.
Reel/Frame 051429/0219 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SPELLING OF ASSIGNEE KYOWA HAKKO KIRIN CO., LTD.'S NAME PREVIOUSLY RECORDED ON REEL 026458 FRAME 0056. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS' INTEREST. Recorded Sep 15, 2011
From: YANAGISAWA, ARATA; UEHARA, KEIJI; MATSUBARA, MASAHIRO; UENO, KIMIHISA; SUZUKI, MICHIHIKO; KUBOYAMA, TAKESHI; YAMAMOTO, KEISUKE; TAMURA, TOMOHIRO
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 026916/0433 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2011
From: YANAGISAWA, ARATA; UEHARA, KEIJI; MATSUBARA, MASAHIRO; UENO, KIMIHISA; SUZUKI, MICHIHIKO; KUBOYAMA, TAKESHI; YAMAMOTO, KEISUKE; TAMURA, TOMOHIRO
To: KYOWO HAKKO KIRIN CO., LTD.
Reel/Frame 026458/0056 →
Priority Claims (1)
JP 2008-203216 · Aug 6, 2008 · national
Continuity (1)
Related Publication 20110201640A1 · Aug 18, 2011